These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12704673)

  • 1. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Iezzi M; Ricci C; Astolfi A; Croci S; Marangoni F; Musiani P; Forni G; Lollini PL
    Int J Cancer; 2003 Jun; 105(3):384-9. PubMed ID: 12704673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice.
    Gavallo F; Di Carlo E; Quaglin E; Jezzi M; Strasly M; Bussolino F; Colombo MP; Nanni P; Lollini PL; Musiani P; Forni G
    J Biol Regul Homeost Agents; 2001; 15(4):351-8. PubMed ID: 11860223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
    Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
    Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.
    Di Carlo E; Rovero S; Boggio K; Quaglino E; Amici A; Smorlesi A; Forni G; Musiani P
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):830s-837s. PubMed ID: 11300480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
    Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD
    Cancer Res; 2003 May; 63(10):2425-33. PubMed ID: 12750262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity.
    Spadaro M; Ambrosino E; Iezzi M; Di Carlo E; Sacchetti P; Curcio C; Amici A; Wei WZ; Musiani P; Lollini PL; Cavallo F; Forni G
    Clin Cancer Res; 2005 Mar; 11(5):1941-52. PubMed ID: 15756020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Anisimov VN; Khavinson VK; Provinciali M; Alimova IN; Baturin DA; Popovich IG; Zabezhinski MA; Imyanitov EN; Mancini R; Franceschi C
    Int J Cancer; 2002 Sep; 101(1):7-10. PubMed ID: 12209581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
    De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
    Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.
    Boggio K; Di Carlo E; Rovero S; Cavallo F; Quaglino E; Lollini PL; Nanni P; Nicoletti G; Wolf S; Musiani P; Forni G
    Cancer Res; 2000 Jan; 60(2):359-64. PubMed ID: 10667588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.
    Boggio K; Nicoletti G; Di Carlo E; Cavallo F; Landuzzi L; Melani C; Giovarelli M; Rossi I; Nanni P; De Giovanni C; Bouchard P; Wolf S; Modesti A; Musiani P; Lollini PL; Colombo MP; Forni G
    J Exp Med; 1998 Aug; 188(3):589-96. PubMed ID: 9687535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.
    Cifaldi L; Quaglino E; Di Carlo E; Musiani P; Spadaro M; Lollini PL; Wolf S; Boggio K; Forni G; Cavallo F
    Cancer Res; 2001 Apr; 61(7):2809-12. PubMed ID: 11306448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
    Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
    Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone.
    Yee LD; Young DC; Rosol TJ; Vanbuskirk AM; Clinton SK
    J Nutr; 2005 May; 135(5):983-8. PubMed ID: 15867269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Re F; Donnini A; Orlando F; Bartozzi B; Di Stasio G; Smorlesi A
    Int J Cancer; 2005 May; 115(1):36-45. PubMed ID: 15688416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
    Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.